To The Moon

Now that my $100 call came to fruition, I've got another. I think we will see $103-104 sooner rather than later, and probably $110ish in Q1 2024. That is decision time to take a little profit or hedge or just stay on the whole time to $120+ target. I do believe we will get a pullback soon where bond yields will retrace a little bit. Multiple pullbacks before the end goal. But I do not expect bond yields to go back much higher without some major catalyst. Probably a spike in oil price would be the only thing to do it. Economic and inflation data is weakening. Trend is your friend for now. Good day bulls.$TLT$ Bullish

$BABA it’s too obvious that it’s going to be down tomorrow and quite a lot, look at the options chain tomorrow and think for yourself…do you think that the MM would rather pay out 11000 calls at the $77 strike or maybe they rather payout 820 puts, same goes for the $76 and the $75 strikes!!!! To the moon right???? $BABA$ Bearish 

Hard to bet against a company with 2.2 million backorders for the cybertruck. What is amazing, is that since the first deliveries, they are averaging 10K orders per day. With the Jupiter model Y coming out mid 2024, I think it will also be the biggest selling vehicle on the planet for 2024 with at least 15 pct greater range and faster charging. Lithium prices are coming down and batteries getting cheaper by the month. Tesla is in a very good position even with weird Elon. The best engineers are at Tesla, and I believe the cybertruck is the most American made vehicle of anything produced.$TSLA$ Bullish

- $5 billion FCF- buying back 4-5% of shares outstanding per year at current valuations- Q3 results showed 8% revenue growth, upped guidance for FY23- great balance sheet: lots of cash on hand, mediocre debt: all aquired at all-time low interest rates- market leader in a market that's going to see secular growth of 8,9% CAGR through 2030- new CEO and new CFO, the latter coming from CFO at consulting giant EY. Those people know which strings to pullAnd even though it traded at 10x forward PE a couple weeks ago, people still saying it's a dying company, no moat, blabla. I laugh at those suckers. Just like I laughed at people not willing to buy Alphabet under $100. Just like I laughed at people dumping oil shares in 2020 at absolute bottom prices 'cause oil is going away'. This is called 'sen

Mañana Jassy finally puts his stamp on the company. His so called coming out party starts with Amazon’s mouthwatering ER and guidance. Expect Amazon’s expenses to be way down as they are not replacing the high attrition rates Amazon encounters in their warehouses and fulfillment centers.AI and robotics are filling the void. Look for big news in the healthcare front too, Watch for a more aggressive Jassy when discussing AI and how they have been incorporating AI into their businesses not starting this year but for the last decade. AD revenue has been on fire and expect a big number there. Unlike Apple, Amazon does break out their AD revenue and the market will hone in on that number. Machine Learning has really aided that business for them. E-commerce is back and in a big way. Gear up for a

Faraday Future(NASDAQ:FFIE) stock is falling recently as theelectric vehicle(EV) company enacts measures tokick a member from its board of directors.Faraday Future will be holding a special meeting of shareholders to vote on the removal of Brian Krolicki from its board. Krolicki is the former Chairman of the board and previously served as the Lieutenant Governor of Nevada.Faraday Future said the following in a filing with the U.S. Securities and Exchange Commission (SEC): “The Company’s operational results are consistently falling short of the goals the Company has set forth in its public filings, and this situation is not improving. We believe that this poor performance is due in significant part to the failings of Mr. Krolicki, who had been designated chairman up until the remedial measu

$Micron Technology(MU)$Coolmask has a point. Semis are drastically underperforming. Not the place to be. Sept 6- October 25 is historically the weakest time of year for the S&P. Combine that with Fed Comments last Friday and it’s best to stay very very light in stocks in the coming weeks. Good time to sit on hands and research emerging leaders for the next run. Keep losses razor thin if you take a position. Remember if you lose 7 percent on a trade, you need to make less than 8 percent to get even. If you lose 50 percent you need to gain back over 100! That’s what kills traders. They have success, maybe even time and time again, until the market (or stock) tops and they are pushed out of the game for good! Happens all the time!

$Snowflake(SNOW)$Snowflake’s(NYSE:SNOW) share price has been battered this year and is down 49% since January. However, like a lot of tech stocks, it has been on the mend since mid-July and has climbed 11% higher over the past month as inflation begins to ease and investor sentiment improves as a result.Snowflake, which specializes in cloud-based data storage and analytics service, went public in 2020 and is one of only a handful of tech stocks owned bylegendary investor Warren Buffett. It was also one of the few IPOs that Buffett has ever gotten in on.

Let’s start up with the current stock price of Bright Minds Biosciences Inc. (DRUG), which is $4.32 to be very precise. The Stock rose vividly during the last session to $1.04 after opening rate of $1.04 while the lowest price it went was recorded $0.9011 before closing at $0.98.Recently in News on June 27, 2022, Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization. Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Alan Kozikowski will no longer serve in the role of Chief Scientific Officer. You can read further

$Novavax(NVAX)$NVAX stock moves higher on the news that its highly anticipated Covid-19 vaccine has been approved for use in American adults.With the blessing of regulators, Novavax must now move to mass produce the vaccine and sell it around the country and wider world. While the company has cleared one important hurdle, it now moves onto new challenges.